Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease

Neurobiology of Aging

Volumn 31, Issue 7, 2010, Pages 1188-1196

  Cheng, Hua ^a   Zhou, Yunhua ^b   Holtzman, David M ^a   Han, Xianlin ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Alzheimer's disease; Apolipoprotein E; APP transgenic mice; PDAPP; Shotgun lipidomics; Sphingolipidomics; Sulfatide; Tg2576

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; SULFATIDE;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIPID BRAIN LEVEL; LIPID METABOLISM; LIPID TRANSPORT; LIPIDOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HOMEOSTASIS; LIPID METABOLISM; LIPOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYELIN SHEATH; SPHINGOMYELINS; SULFOGLYCOSPHINGOLIPIDS;

EID: 77952880682     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.07.020     Document Type: Article

References (40)

1. Arelin K., Kinoshita A., Whelan C.M., Irizarry M.C., Rebeck G.W., Strickland D.K., Hyman B.T. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res. 2002, 104:38-46.
2. Bales K.R., Dodart J.C., DeMattos R.B., Holtzman D.M., Paul S.M. Apolipoprotein E, amyloid, and Alzheimer disease. Mol. Interv. 2002, 2:363-375.
3. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
4. Bosio A., Binczek E., Stoffel W. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13280-13285.
5. Bosio A., Bussow H., Adam J., Stoffel W. Galactosphingolipids and axono-glial interaction in myelin of the central nervous system. Cell Tissue Res. 1998, 292:199-210.
6. Cheng H., Xu J., McKeel D.W., Han X. Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. 2003, 49:809-818.
7. Cheng H., Guan S., Han X. Abundance of triacylglycerols in ganglia and their depletion in diabetic mice: implications for the role of altered triacylglycerols in diabetic neuropathy. J. Neurochem. 2006, 97:1288-1300.
8. Cheng H., Jiang X., Han X. Alterations in lipid homeostasis of mouse dorsal root ganglia induced by apolipoprotein E deficiency: a shotgun lipidomics study. J. Neurochem. 2007, 101:57-76.
9. Coetzee T., Fujita N., Dupree J., Shi R., Blight A., Suzuki K., Popko B. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 1996, 86:209-219.
10. Coetzee T., Dupree J.L., Popko B. Demyelination and altered expression of myelin-associated glycoprotein isoforms in the central nervous system of galactolipid-deficient mice. J. Neurosci. Res. 1998, 54:613-622.
11. Fryer J.D., Taylor J.W., DeMattos R.B., Bales K.R., Paul S.M., Parsadanian M., Holtzman D.M. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 2003, 23:7889-7896.
12. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano P., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
13. Gearing M., Schneider J.A., Robbins R.S., Hollister R.D., Mori H., Games D., Hyman B.T., Mirra S.S. Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1995, 54:833-841.
14. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996, 16:4491-4500.
15. Han X., Holtzman D.M., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82:809-818.
16. Han X., Cheng H., Fryer J.D., Fagan A.M., Holtzman D.M. Novel role for apolipoprotein E in the central nervous system: modulation of sulfatide content. J. Biol. Chem. 2003, 278:8043-8051.
17. Han X., Fagan A.M., Cheng H., Morris J.C., Xiong C., Holtzman D.M. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 2003, 54:115-119.
18. Han X., Yang J., Cheng H., Ye H., Gross R.W. Towards fingerprinting cellular lipidomes directly from biological samples by two-dimensional electrospray ionization mass spectrometry. Anal. Biochem. 2004, 330:317-331.
19. Han X., Gross R.W. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of the cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2005, 24:367-412.
20. Han X. Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stages of Alzheimer's disease: a tale of shotgun lipidomics. J. Neurochem. 2007, 103(s1):171-179.
21. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., Paul S.M. In vivo expression of apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 1999, 103:R15-R21.
22. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2892-2897.
23. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizarry M.C., Hyman B.T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 2000, 47:739-747.
24. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
25. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997, 56:965-973.
26. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
27. Jiang X., Cheng H., Yang K., Gross R.W., Han X. Alkaline methanolysis of lipid extracts extends shotgun lipidomics analyses to the low abundance regime of cellular sphingolipids. Anal. Biochem. 2007, 371:135-145.
28. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., Koo E.H. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 2000, 106:1159-1166.
29. Kuo Y.M., Crawford F., Mullan M., Kokjohn T.A., Emmerling M.R., Weller R.O., Roher A.E. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol. Med. 2000, 6:430-439.
30. Marcus J., Honigbaum S., Shroff S., Honke K., Rosenbluth J., Dupree J.L. Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 2006, 53:372-381.
31. Molander-Melin M., Pernber Z., Franken S., Gieselmann V., Mansson J.E., Fredman P. Accumulation of sulfatide in neuronal and glial cells of arylsulfatase A deficient mice. J. Neurocytol. 2004, 33:417-427.
32. Nagy Z. The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J. Cell. Mol. Med. 2005, 9:531-541.
33. Pernber Z., Molander-Melin M., Berthold C.H., Hansson E., Fredman P. Expression of the myelin and oligodendrocyte progenitor marker sulfatide in neurons and astrocytes of adult rat brain. J. Neurosci. Res. 2002, 69:86-93.
34. Van Uden E., Kang D.E., Koo E.H., Masliah E. LDL receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis. Microsc. Res. Tech. 2000, 50:268-272.
35. von Figura K., Gieselmann V., Jaeken J. Metachromatic leukodystrophy: lysosomal disorders. The Metabolic and Molecular Bases of Inherited Diseases 2001, 3695-3724. McGraw-Hill, New York. 8th ed. H.S. Sachdev, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
36. Vos J.P., Lopes-Cardozo M., Gadella B.M. Metabolic and functional aspects of sulfogalactolipids. Biochim. Biophys. Acta 1994, 1211:125-149.
37. Yang K., Zhao Z., Gross R.W., Han X. Shotgun lipidomics identifies a paired rule for the presence of isomeric ether phospholipid molecular species. PLoS ONE 2007, 2:e1368.
38. Zeng Y., Cheng H., Jiang X., Han X. Endosomes and lysosomes play distinct roles in sulfatide-induced neuroblastoma apoptosis: potential mechanisms contributing to abnormal sulfatide metabolism in related neuronal diseases. Biochem. J. 2008, 410:81-92.
39. Zeng Y., Han X. Sulfatides facilitate apolipoprotein E-mediated amyloid-b peptide clearance through an endocytotic pathway. J. Neurochem. 2008, 106:1275-1286.
40. Zetterberg H., Andreasson U. Update on Alzheimer's and Parkinson's diseases. Aging Health 2007, 3:305-307.